Screener
Sana Biotechnology SANA Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development related success payments and contingent consideration | 8,433 | 1,957 |
| General and administrative | 11,462 | 11,484 |
| Total operating expenses | 48,614 | 50,630 |
| Loss from operations | (48,614) | (50,630) |
| Interest income, net | 951 | 992 |
| Other income, net | 453 | 249 |
| Net loss | $(47,210) | $(49,389) |
| Net loss per common share – basic and diluted | $(0.17) | $(0.21) |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's operating income?
- Sana Biotechnology (SANA) reported operating income of -$48.61M in Q1 2026.
- How has Sana Biotechnology's operating income changed year-over-year?
- Sana Biotechnology's operating income increased by 4.0% year-over-year, from -$50.63M to -$48.61M.
- What is the long-term trend for Sana Biotechnology's operating income?
- Over 4 years (2021 to 2025), Sana Biotechnology's operating income has grown at a -8.5% compound annual growth rate (CAGR), from -$356.91M to -$250.32M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Sana Biotechnology's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude